DDInter256 DDInter1140
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Butabarbital {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Butabarbital {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Flecainide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Butabarbital {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Metoclopramide
Metoclopramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Butabarbital {u} (Compound) causes {v} (Side Effect) Hepatocellular injury
Hepatocellular injury {u} (Side Effect) is caused by {v} (Compound) Telithromycin
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoclopramide
Metoclopramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Butabarbital (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mefloquine (Compound)
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Butabarbital (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Flecainide (Compound) and Flecainide (Compound) resembles Mefloquine (Compound)
Butabarbital (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Metoclopramide (Compound) and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Butabarbital (Compound) causes Hepatocellular injury (Side Effect) and Hepatocellular injury (Side Effect) is caused by Telithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Mefloquine